top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Ariel Hurley Biography and Net Worth

Insider of Blueprint Medicines

Ariel Hurley CPA serves as Vice President - Finance, Controller of the Company. She has served as our vice president, finance and controller since February 2019. Ms. Hurley previously served as our Senior Director, Controller from January 2016 to December 2018 and as our Director, Controller from September 2014 to December 2015. Prior to joining us, Ms. Hurley served in various accounting and finance roles at Millennium Pharmaceuticals, Inc. (now a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) from December 2005 to September 2014. Ms. Hurley began her career at Deloitte & Touche, LLP and has over 20 years of experience in finance and accounting roles of increasing responsibility. She earned her certified public accountant license in Massachusetts. Ms. Hurley received a B.S. in accounting from Providence College.

What is Ariel Hurley's net worth?: The estimated net worth of Ariel Hurley is at least $1.32 million as of December 22nd, 2023. Ms. Hurley owns 14,324 shares of Blueprint Medicines stock worth more than $1,321,532 as of April 24th. This net worth evaluation does not reflect any other investments that Ms. Hurley may own. Learn More about Ariel Hurley's net worth.
How old is Ariel Hurley?: Ms. Hurley is currently 50 years old. There are 8 older executives and no younger executives at Blueprint Medicines. The oldest executive at Blueprint Medicines is Dr. Christopher K. Murray Ph.D., Senior VP of Technical Operations and Chief Technical Operations & Quality Officer, who is 60 years old. Learn More on Ariel Hurley's age.
How do I contact Ariel Hurley?: The corporate mailing address for Ms. Hurley and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Ariel Hurley's contact information.
Has Ariel Hurley been buying or selling shares of Blueprint Medicines?: Ariel Hurley has not been actively trading shares of Blueprint Medicines during the past quarter. Most recently, Ariel Hurley sold 714 shares of the business's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $90.00, for a transaction totalling $64,260.00. Following the completion of the sale, the insider now directly owns 14,324 shares of the company's stock, valued at $1,289,160. Learn More on Ariel Hurley's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 24 times. They sold a total of 172,543 shares worth more than $13,714,414.59. The most recent insider tranaction occured on March, 28th when CFO Michael Landsittel sold 5,000 shares worth more than $475,000.00. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 3/28/2024.

Ariel Hurley Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/22/2023	Sell	714	$90.00	$64,260.00	14,324
3/10/2022	Sell	2,339	$57.15	$133,673.85
3/7/2022	Sell	256	$56.19	$14,384.64
3/3/2022	Sell	761	$60.27	$45,865.47
9/23/2021	Sell	600	$110.00	$66,000.00
8/17/2021	Sell	1,350	$91.93	$124,105.50	10,747
10/7/2020	Sell	600	$100.00	$60,000.00	10,584
8/17/2020	Sell	700	$75.00	$52,500.00	10,684
6/9/2020	Sell	700	$75.00	$52,500.00	10,684
12/16/2019	Sell	415	$75.00	$31,125.00	415
12/4/2019	Sell	192	$77.25	$14,832.00
10/17/2019	Sell	415	$75.00	$31,125.00	415
9/16/2019	Sell	415	$78.14	$32,428.10	415
8/15/2019	Sell	415	$84.02	$34,868.30	415
7/19/2019	Sell	115	$100.00	$11,500.00	115
7/15/2019	Sell	830	$94.98	$78,833.40	830
6/17/2019	Sell	1,405	$98.22	$137,999.10	830
6/13/2019	Sell	2,733	$88.04	$240,613.32
3/15/2019	Sell	415	$85.55	$35,503.25	415

Ariel Hurley Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $92.26

$90.43

$93.74

50 Day Range

MA: $90.67

$85.18

$99.79

2 Week Range

Now: $92.26

$43.89

$101.00

Volume

588,540 shs

Average Volume

764,526 shs

Market Capitalization

$5.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad